Autoimmune Encephalitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Autoimmune Encephalitis (US)
Autoimmune encephalitis is a heterogeneous group of immune-mediated inflammatory brain disorders characterized by subacute cognitive decline, psychiatric symptoms, seizures, movement disorders, autonomic dysfunction, and altered consciousness. The best-characterized subtypes are antibody-mediated syndromes targeting neuronal cell-surface antigens, including NMDA, GABAB, and AMPA receptors. The current treatment landscape relies on off-label interventions. Acute attacks are managed with high-dose corticosteroids or plasma exchange, while relapsing cases are typically treated with maintenance immunosuppressants like rituximab, intravenous immunoglobulin, or mycophenolate mofetil. A critical unmet need exists for FDA-approved, disease-specific therapies.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed autoimmune encephalitis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed autoimmune encephalitis patients?
- How are tocilizumab and rituximab integrated into the treatment algorithm, and what is their source of business?
- What percentage of autoimmune encephalitis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of autoimmune encephalitis patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Geography: United States
Key drugs covered: Rituximab, intravenous immunoglobulins, tocilizumab, Enspryng, Imaavy, Soliris, Vyvgart, Ultomiris, Rystiggo, corticosteroids
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
